BAY 60-2770

BAY 60-2770 is an NO-independent activator of sGC (soluble guanylyl cyclase) with EC50 of 5.4 nM; demonstrates vasodilator activity in the pulmonary and systemic vascular beds that is enhanced by ODQ and NOS inhibition.

Research Areas >> Cardiovascular Disease

Signaling Pathways >> GPCR/G Protein >> Guanylate Cyclase

BAY 60-2770 (0.1-0.3 mg/Kg; p.o.) attenuates liver fibrosis in two rat models[1]. BAY 60-2770 (1 mg/kg; p.o.; daily from the 10th to the 12th week) results in amelioration of bladder dysfunction in high-fat obese mice[2]. Animal Model: Obese mice[2] Dosage: 1 mg/kg Administration: p.o.; daily from the 10th to the 12th week Result: Ameliorates detrusor dysfunction in obese mice.

[1]. Knorr A, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung. 2008;58(2):71-80.

[2]. Leiria LO, et al. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. J Urol. 2014 Feb;191(2):539-47.